Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.
Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.
Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.
Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.
Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.
Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.
Bristol Myers Squibb (NYSE:BMY) has reported fourth quarter revenues of $12.0 billion, marking an 8% increase year-over-year, and full-year revenues of $46.4 billion. The fourth quarter earnings per share (EPS) stand at $1.07 (GAAP) and $1.83 (non-GAAP), with full-year EPS at $3.12 and $7.51 respectively, reflecting a 17% growth in non-GAAP EPS. The company has authorized a $15 billion share repurchase initiative and announced a $5 billion accelerated share repurchase agreement for Q1 2022. Guidance for 2022 includes projected revenues of approximately $47 billion.
Bristol Myers Squibb (NYSE: BMY) announced that the CHMP of the EMA has recommended the approval of Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy for adult patients with relapsed or refractory aggressive lymphomas. This recommendation follows the successful results of the TRANSCEND NHL 001 trial, the largest pivotal trial for this indication, and the TRANSCEND WORLD study. The final decision from the European Commission is anticipated within 67 days and will affect all EU member states, as well as Iceland, Norway, and Liechtenstein.
BioAtla (Nasdaq: BCAB) announced a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to explore its lead candidates, BA3011 and BA3021, in combination with Opdivo (nivolumab) for solid tumors. BioAtla will sponsor the trials and bear execution costs, while Bristol Myers Squibb will supply Opdivo. Both candidates target AXL and ROR2, which are significant in various cancers, especially after prior anti-PD-1 therapy. This collaboration aims to enhance treatment options for patients with unmet medical needs.
Bristol Myers Squibb (NYSE:BMY) has expanded its collaboration with Arsenal Biosciences to develop next-generation T cell therapies for solid tumors. This follows an option exercise from their December 2020 agreement, which includes undisclosed financial milestone payments. Bristol Myers Squibb will be responsible for the development and commercialization of the new preclinical candidates. The collaboration highlights the potential of ArsenalBio's programmable cell therapy technology, aiming to improve patient outcomes in cancer treatment.
Pyramid Biosciences has appointed Dr. Brian Lestini as the new Chief Executive Officer, succeeding co-founder Dr. Kollol Pal, who remains as Chief Scientific Officer. Dr. Lestini joined the company in March 2021 and has extensive experience in oncology, notably at Bristol-Myers Squibb (NYSE: BMY). The company continues to focus on its clinical-stage pipeline, particularly the lead program PBI-200, a TRK inhibitor targeting brain cancers. This leadership change aims to further enhance the company’s growth and development of precision oncology therapies.
Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to develop allogeneic cell therapies targeting hematologic malignancies and solid tumors. Century will receive
Bristol Myers Squibb (NYSE:BMY) highlighted its growth strategy during the J.P. Morgan Healthcare Conference. The company announced a $5 billion share repurchase plan for Q1 2022, alongside guidance for 2022 total revenues of approximately $47 billion. Key drivers for growth include a diverse product portfolio expected to generate $10-$13 billion in revenue by 2025, promising mid- to late-stage assets, and a robust early-stage pipeline. Additionally, BMY reaffirmed its long-term financial targets, emphasizing strong cash flows of $45-$50 billion from 2022 to 2024.
Bristol Myers Squibb (BMY) has expanded its partnership with ZS, a professional services firm, to enhance its worldwide commercial analytics capabilities. This agreement builds on a successful collaboration initiated in 2015, focusing on BMS’s Business Insights & Analytics group. The partnership aims to utilize data science, marketing mix strategies, forecasting, and brand analytics across over 65 markets. ZS, with over 35 years of experience, is committed to helping BMS drive impactful decision-making to improve patient outcomes.
Bristol Myers Squibb (NYSE: BMY) will present at J.P. Morgan’s 40th Annual Virtual Healthcare Conference on January 10, 2022. The formal presentation by Giovanni Caforio, M.D., Board Chair and CEO, is scheduled for 7:30 a.m. ET. The event will be webcast live, with related materials available beforehand. A replay and archived version will be accessible after the event. Bristol Myers Squibb is committed to discovering and delivering innovative medicines for serious diseases.
Bristol Myers Squibb (NYSE:BMY) will announce its fourth quarter 2021 results on
Participants can access the live webcast at BMS.com or through dial-in options. A replay will be available three hours post-call until
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
What is Bristol-Myers Squibb's core business?
Where is Bristol-Myers Squibb headquartered?
What was Bristol-Myers Squibb's revenue for fiscal 2022?
What is a significant focus area for Bristol-Myers Squibb?
How much of Bristol-Myers Squibb's total sales come from the U.S. market?
What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?
What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?
What is SpliceCore®?
When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?
What is Bristol-Myers Squibb's mission?
